Preserflo微型分流器植入5年后的内皮细胞丢失：约2例。
Endothelial cell loss 5 years after Preserflo MicroShunt implantation: About two cases.
作者信息
Chamard Chloé, Hammoud Sirine, Bluwol Elisa, Lachkar Yves
机构信息
Department of Ophthalmology, Gui de Chauliac Hospital, Montpellier, F-34000, France.
Univ. Montpellier, Inserm, Neuropsychiatry: Epidemiological and Clinical Research, PSNREC, Montpellier, France.
出版信息
Am J Ophthalmol Case Rep. 2021 Dec 8;25:101238. doi: 10.1016/j.ajoc.2021.101238. eCollection 2022 Mar.
PURPOSE
Preserflo MicroShunt is a minimally-invasive glaucoma drainage micro-tube used to shunt aqueous humor from the anterior chamber to the subtenon space. The safety of the procedure was considered satisfactory with a majority of minor side effects.
OBSERVATION
We describe the 5 year endothelial cell loss after Preserflo implantation in 2 primary open angle glaucoma patients. The case 1 presented a device-cornea touch after a backward migration of the device. The case 2 presented a modified aspect of the device compatible with an inflammatory reaction. Both cases were explanted.
CONCLUSION
As described in Ahmed glaucoma valve, Xen gel stent and Cypass, Preserflo MicroShunt can lead to endothelial cell loss in some cases. A long-term prospective study with pre and postoperative endothelial cell count and AS-OCT or UBM evaluation of the device positioning would be of great interest to assess the real impact of Preserflo MicroShunt and risk factors for endothelial cell loss.
目的
Preserflo微型分流器是一种用于将房水从前房引流至眼球筋膜下间隙的微创青光眼引流微管。该手术的安全性被认为令人满意，大多数为轻微副作用。
观察
我们描述了2例原发性开角型青光眼患者植入Preserflo后5年的内皮细胞丢失情况。病例1在装置向后移位后出现装置-角膜接触。病例2出现与炎症反应相符的装置改变外观。两例均取出装置。
结论
如在艾哈迈德青光眼阀、Xen凝胶支架和Cypass中所描述的那样，Preserflo微型分流器在某些情况下可导致内皮细胞丢失。进行术前和术后内皮细胞计数以及对装置位置进行AS-OCT或UBM评估的长期前瞻性研究，对于评估Preserflo微型分流器的实际影响和内皮细胞丢失的危险因素将非常有意义。
Zotero 插件